January 21, 2019
SPT Staff
Ontruzant (trastuzumab-dttb) is indicated for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer.


Jennifer Barrett, Associate Editor
Crizanlizumab under evaluation for the prevention of vaso-occlusive crises in patients of all genotypes with sickle cell disease.
Jennifer Barrett, Associate Editor
Andexxa (coagulation factor Xa [recombinant], inactivated-zhzo) was previously launched under an Early Supply Program with Generation 1 product. 
Gina Columbus
Sprycel plus chemotherapy demonstrated a three-year event-free survival benefit during clinical trials.
Jennifer Barrett, Associate Editor
The FDA approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to Herceptin for the treatment of HER2-overexpressing breast cancer. 
Jennifer Barrett, Associate Editor
Evolocumab is approved as an adjunct to diet and other LDL cholesterol-lowering therapies in patients with primary hyperlipidemia and homozygous familial hypercholesterolemia.
About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us